Evaluation the efficiency of coenzyme Q10 (ubiquinone) supplementation on cisplatin-induced nephrotoxicity
Phase 3
Recruiting
- Conditions
- ephrotoxicity due to cisplatin.Nephropathy induced by other drugs, medicaments and biological substancesN14.1
- Registration Number
- IRCT20211205053287N1
- Lead Sponsor
- Shahre-kord University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 46
Inclusion Criteria
1- Age between 80-20 years,
2- Do not take antioxidant and anti-inflammatory supplements for at least 1 month before the start of the study
3- Willingness to cooperate in the research project and completing the informed consent form Community Verified icon
Exclusion Criteria
1- Changing the method of drug treatment and taking antioxidant and anti-inflammatory supplements during the study period
2- Changing lifestyle (changing diet, physical activity and level of mental stress) during the study
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method ephrotoxicity due to cisplatin. Timepoint: In patients receiving cisplatin, the tests are checked once before starting (Q10) supplementation and once after supplementation (2 months later). Method of measurement: Check blood urea nitrogen (BUN) and creatinine (Cr) for patients.
- Secondary Outcome Measures
Name Time Method